A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Eli Lilly and Company
Eli Lilly and Company
Dana-Farber Cancer Institute
Eli Lilly and Company
AstraZeneca
IRCCS San Raffaele
University of Maryland, Baltimore
Hoffmann-La Roche
Hoffmann-La Roche
Medical University of Vienna
Hoffmann-La Roche
GlaxoSmithKline
Tampere University Hospital
East Valley Hematology and Oncology Medical Group